American Bio Medica Corporation (ABMC)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2022 | -193 Thousand USD | -135.22% |
| 2021 | 548 Thousand USD | -55.74% |
| 2020 | 1.23 Million USD | 4.56% |
| 2019 | 1.18 Million USD | -8.07% |
| 2018 | 1.28 Million USD | -35.5% |
| 2017 | 1.99 Million USD | -19.8% |
| 2016 | 2.49 Million USD | -12.78% |
| 2015 | 2.85 Million USD | -6.76% |
| 2014 | 3.06 Million USD | -14.28% |
| 2013 | 3.57 Million USD | 6.82% |
| 2012 | 3.34 Million USD | -13.73% |
| 2011 | 3.87 Million USD | -5.65% |
| 2010 | 4.1 Million USD | -0.17% |
| 2009 | 4.11 Million USD | -21.78% |
| 2008 | 5.26 Million USD | -8.2% |
| 2007 | 5.73 Million USD | -15.76% |
| 2006 | 6.8 Million USD | 12.54% |
| 2005 | 6.04 Million USD | -8.33% |
| 2004 | 6.59 Million USD | -5.89% |
| 2003 | 7 Million USD | 20.07% |
| 2002 | 5.83 Million USD | 0.0% |
| 2001 | - USD | -100.0% |
| 2000 | 4.05 Million USD | 10.02% |
| 1999 | 3.68 Million USD | 234.73% |
| 1998 | 1.1 Million USD | 213.38% |
| 1997 | 351.01 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q2 | - USD | -100.0% |
| 2023 Q1 | 74 Thousand USD | 152.86% |
| 2023 Q3 | - USD | 0.0% |
| 2022 Q2 | -73 Thousand USD | -360.71% |
| 2022 Q1 | 28 Thousand USD | -77.24% |
| 2022 FY | -193 Thousand USD | -135.22% |
| 2022 Q4 | -140 Thousand USD | -1455.56% |
| 2022 Q3 | -9000.00 USD | 87.67% |
| 2021 Q4 | 123 Thousand USD | -33.51% |
| 2021 FY | 548 Thousand USD | -55.74% |
| 2021 Q1 | 105 Thousand USD | -54.35% |
| 2021 Q2 | 136 Thousand USD | 29.52% |
| 2021 Q3 | 185 Thousand USD | 36.03% |
| 2020 FY | 1.23 Million USD | 4.56% |
| 2020 Q2 | 582 Thousand USD | 206.32% |
| 2020 Q3 | 235 Thousand USD | -59.62% |
| 2020 Q1 | 190 Thousand USD | -11.21% |
| 2020 Q4 | 230 Thousand USD | -2.13% |
| 2019 Q1 | 306 Thousand USD | 163.79% |
| 2019 Q2 | 306 Thousand USD | 0.0% |
| 2019 Q3 | 359 Thousand USD | 17.32% |
| 2019 Q4 | 214 Thousand USD | -40.39% |
| 2019 FY | 1.18 Million USD | -8.07% |
| 2018 FY | 1.28 Million USD | -35.5% |
| 2018 Q4 | 116 Thousand USD | -68.13% |
| 2018 Q3 | 364 Thousand USD | -16.7% |
| 2018 Q1 | 372 Thousand USD | 23.59% |
| 2018 Q2 | 437 Thousand USD | 17.47% |
| 2017 Q1 | 565 Thousand USD | 4.82% |
| 2017 Q3 | 566 Thousand USD | 0.18% |
| 2017 Q4 | 301 Thousand USD | -46.82% |
| 2017 FY | 1.99 Million USD | -19.8% |
| 2017 Q2 | 565 Thousand USD | 0.0% |
| 2016 Q4 | 539 Thousand USD | -11.78% |
| 2016 FY | 2.49 Million USD | -12.78% |
| 2016 Q1 | 630 Thousand USD | 17.1% |
| 2016 Q2 | 709 Thousand USD | 12.54% |
| 2016 Q3 | 611 Thousand USD | -13.82% |
| 2015 Q4 | 538 Thousand USD | -29.86% |
| 2015 Q2 | 849 Thousand USD | 21.29% |
| 2015 Q3 | 767 Thousand USD | -9.66% |
| 2015 FY | 2.85 Million USD | -6.76% |
| 2015 Q1 | 700 Thousand USD | 4.32% |
| 2014 FY | 3.06 Million USD | -14.28% |
| 2014 Q1 | 877 Thousand USD | -3.73% |
| 2014 Q2 | 791 Thousand USD | -9.81% |
| 2014 Q4 | 671 Thousand USD | -7.19% |
| 2014 Q3 | 723 Thousand USD | -8.6% |
| 2013 Q3 | 906 Thousand USD | -6.5% |
| 2013 Q4 | 911 Thousand USD | 0.55% |
| 2013 FY | 3.57 Million USD | 6.82% |
| 2013 Q2 | 969 Thousand USD | 23.28% |
| 2013 Q1 | 786 Thousand USD | 75.45% |
| 2012 Q4 | 448 Thousand USD | -49.72% |
| 2012 Q3 | 891 Thousand USD | -14.49% |
| 2012 Q2 | 1.04 Million USD | 8.32% |
| 2012 Q1 | 962 Thousand USD | -3.51% |
| 2012 FY | 3.34 Million USD | -13.73% |
| 2011 Q1 | 762 Thousand USD | -6.96% |
| 2011 FY | 3.87 Million USD | -5.65% |
| 2011 Q3 | 966 Thousand USD | -16.07% |
| 2011 Q4 | 997 Thousand USD | 3.21% |
| 2011 Q2 | 1.15 Million USD | 51.05% |
| 2010 Q2 | 1.46 Million USD | 53.63% |
| 2010 FY | 4.1 Million USD | -0.17% |
| 2010 Q4 | 819 Thousand USD | -6.61% |
| 2010 Q3 | 877 Thousand USD | -39.97% |
| 2010 Q1 | 951 Thousand USD | -6.31% |
| 2009 Q3 | 1.02 Million USD | -11.33% |
| 2009 FY | 4.11 Million USD | -21.78% |
| 2009 Q1 | 919 Thousand USD | 28.53% |
| 2009 Q2 | 1.15 Million USD | 25.79% |
| 2009 Q4 | 1.01 Million USD | -0.98% |
| 2008 Q1 | 1.42 Million USD | -10.31% |
| 2008 FY | 5.26 Million USD | -8.2% |
| 2008 Q2 | 1.61 Million USD | 13.38% |
| 2008 Q4 | 715 Thousand USD | -52.33% |
| 2008 Q3 | 1.5 Million USD | -7.29% |
| 2007 Q3 | 1.41 Million USD | -2.94% |
| 2007 Q4 | 1.59 Million USD | 12.12% |
| 2007 FY | 5.73 Million USD | -15.76% |
| 2007 Q1 | 1.25 Million USD | -26.5% |
| 2007 Q2 | 1.46 Million USD | 16.12% |
| 2006 FY | 6.8 Million USD | 12.54% |
| 2006 Q1 | 1.64 Million USD | 157.77% |
| 2006 Q2 | 1.77 Million USD | 7.98% |
| 2006 Q3 | 1.67 Million USD | -5.58% |
| 2006 Q4 | 1.71 Million USD | 2.33% |
| 2005 Q3 | 2 Million USD | 13.95% |
| 2005 Q4 | 637 Thousand USD | -68.17% |
| 2005 Q2 | 1.75 Million USD | 6.88% |
| 2005 Q1 | 1.64 Million USD | 20.1% |
| 2005 FY | 6.04 Million USD | -8.33% |
| 2004 Q1 | 1.72 Million USD | 15.64% |
| 2004 Q4 | 1.36 Million USD | -26.37% |
| 2004 Q2 | 1.64 Million USD | -4.59% |
| 2004 Q3 | 1.85 Million USD | 13.02% |
| 2004 FY | 6.59 Million USD | -5.89% |
| 2003 Q2 | 1.75 Million USD | 18.53% |
| 2003 Q1 | 1.47 Million USD | 24.92% |
| 2003 Q4 | 1.49 Million USD | -34.79% |
| 2003 Q3 | 2.28 Million USD | 30.35% |
| 2003 FY | 7 Million USD | 20.07% |
| 2002 FY | 5.83 Million USD | 0.0% |
| 2002 Q1 | 1.3 Million USD | 0.0% |
| 2002 Q2 | 1.48 Million USD | 13.37% |
| 2002 Q3 | 1.9 Million USD | 28.03% |
| 2002 Q4 | 1.18 Million USD | -37.68% |
| 2001 FY | - USD | -100.0% |
| 2001 Q3 | 936 Thousand USD | -13.89% |
| 2001 Q2 | 1.08 Million USD | 1.21% |
| 2001 Q1 | 1.07 Million USD | -2.27% |
| 2000 Q2 | 1.41 Million USD | 48.27% |
| 2000 FY | 4.05 Million USD | 10.02% |
| 2000 Q3 | 1.32 Million USD | -6.09% |
| 2000 Q1 | 953 Thousand USD | -1.14% |
| 2000 Q4 | 1.09 Million USD | -17.18% |
| 1999 Q2 | 1.04 Million USD | 21.65% |
| 1999 Q3 | 1.08 Million USD | 4.21% |
| 1999 FY | 3.68 Million USD | 234.73% |
| 1999 Q4 | 964 Thousand USD | -11.48% |
| 1999 Q1 | 859 Thousand USD | -12.17% |
| 1998 Q3 | 1.05 Million USD | 32.37% |
| 1998 Q4 | 978 Thousand USD | -6.95% |
| 1998 FY | 1.1 Million USD | 213.38% |
| 1998 Q1 | - USD | -100.0% |
| 1998 Q2 | 794 Thousand USD | 0.0% |
| 1997 Q4 | 300 Thousand USD | 0.0% |
| 1997 FY | 351.01 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Arrayit Corporation | 2.57 Million USD | 107.495% |
| Atlantic International Corp. | -154.23 Thousand USD | -25.135% |
| Biocept, Inc. | -2.58 Million USD | 92.525% |
| Bioqual, Inc. | 7.42 Million USD | 102.598% |
| CardioGenics Holdings Inc | - USD | Infinity% |
| DermTech, Inc. | 276 Thousand USD | 169.928% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 6.73 Billion USD | 100.003% |
| HTG Molecular Diagnostics, Inc. | 1.79 Million USD | 110.758% |
| iMD Companies, Inc. | -23.63 Thousand USD | -716.516% |
| IDenta Corp. | 662.97 Thousand USD | 129.111% |
| Interpace Biosciences, Inc. | 23.04 Million USD | 100.838% |
| Integrative Health Technologies, Inc. | 77.57 Thousand USD | 348.804% |
| InVitro International | 635.98 Thousand USD | 130.347% |
| Lumos Diagnostics Holdings Limited | 6.56 Million USD | 102.941% |
| Many Bright Ideas Technologies Inc. | - USD | Infinity% |
| Medical Imaging Corp. | 1.09 Million USD | 117.663% |
| NovelStem International Corp. | 12 Thousand USD | 1708.333% |
| Optigenex Inc. | -102.96 Thousand USD | -87.441% |
| PharmChem, Inc. | 3.9 Million USD | 104.943% |
| Proteome Sciences plc | 2.09 Million USD | 109.205% |
| Response Genetics, Inc | 3.94 Million USD | 104.896% |
| Rennova Health, Inc. | 6.26 Million USD | 103.079% |
| RushNet, Inc. | 1.1 Million USD | 117.472% |
| ScreenPro Security Inc. | 856.57 Thousand USD | 122.532% |
| Stella Diagnostics Inc. | - USD | Infinity% |
| StageZero Life Sciences Ltd. | -403.74 Thousand USD | 52.198% |
| Todos Medical Ltd. | 4.31 Million USD | 104.478% |